Susquehanna Fundamental Investments’s ImmunityBio IBRX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$147K	Buy	+23,185	New	+$153K	﹤0.01%	872
2021 Q4	–	Sell	-13,169	Closed	-$128K	–	1591
2021 Q3	$128K	Sell	13,169 -9,494	-42%	-$104K	﹤0.01%	1600
2021 Q2	$324K	Buy	22,663 +8,100	+56%	+$134K	0.01%	1341
2021 Q1	$346K	Buy	14,563 +100	+0.7%	+$2.59K	0.01%	1262
2020 Q4	$193K	Sell	14,463 -58,637	-80%	-$564K	﹤0.01%	1359
2020 Q3	$507K	Buy	+73,100	New	+$729K	0.02%	872

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna Fundamental Investments's IBRX Position: Q2 2024 in Review

Susquehanna Fundamental Investments opened a new position in ImmunityBio (IBRX) in Q2 2024: 23,185 shares worth $147K. The stake represents ﹤0.01% of the portfolio and ranks #872 among its holdings. This is a return to the name: Susquehanna Fundamental Investments previously reported a position in IBRX as recently as Q3 2021.

Susquehanna Fundamental Investments first reported a position in IBRX in Q3 2020 and has held it in 6 quarters since. The position peaked at $507K in Q3 2020. 193 funds tracked by Wall St. Rank hold IBRX as of Q2 2024.

Susquehanna Fundamental Investments held 23,185 shares of ImmunityBio worth $147K as of Q2 2024.
ImmunityBio was a new Susquehanna Fundamental Investments position in Q2 2024.
ImmunityBio made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q2 2024, its #872 holding.
Susquehanna Fundamental Investments first reported a position in ImmunityBio in Q3 2020 and has held it in 6 quarters since.
Susquehanna Fundamental Investments's ImmunityBio position peaked at $507K in Q3 2020.
193 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2024.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2024, filed 15 Aug 2024.